Year All20262025 June 8, 2026 Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China June 8, 2026 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China June 1, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 28, 2026 Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference May 14, 2026 Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine May 13, 2026 Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update May 4, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 1, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 30, 2026 Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update March 30, 2026 Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
June 8, 2026 Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
May 14, 2026 Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
March 30, 2026 Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026 Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease